Therefore, GLP-1 may reduce the likelihood of non-alcoholic fatty liver disease (NAFLD) in individuals with T2DM by directly interacting with hepatic GLP-1 receptors. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.